We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 63.00 | 61.00 | 65.00 | 63.00 | 63.00 | 63.00 | 0.00 | 07:30:25 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.80 | 14.85M |
From Apr 2019 to Apr 2024
TIDMNSCI
RNS Number : 0830J
NetScientific PLC
26 June 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Glycotest Update
London, UK - June 26(th) 2017 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, provides an update on the series A fundraising being undertaken by its portfolio company Glycotest, a US-based diagnostics company, as outlined in the Circular issued to shareholders following the Company's placing and subscription of new shares on 26 May 2017 (the "Circular").
The Company continues to anticipate closing the Series A round within the second half of 2017, but does not now expect to sign the relevant documentation by the end of June 2017, as was previously stated as the Company's aim in the Circular.
As at 31 December 2016 the NetScientific had invested GBP2.4 million in Glycotest. The Company expects that the delay will lead to an increase in its GBP0.5m expected spend in Glycotest in 2017, as stated in the Circular, but with overall spend remaining under GBP1.0m in 2017.
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800 François R. Martelet, M.D., CEO Ian Postlethwaite, CFO Consilium Strategic Communications Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / netscientific@consilium-comms.com Jessica Hodgson / Chris Welsh / Laura Thornton Stifel Nicolaus Europe Tel: +44 (0) 20 7710 7600 Limited (NOMAD and Broker) Jonathan Senior / David Arch / Ben Maddison
About NetScientific
NetScientific is an IP commercialisation group focused on healthcare with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net
About Glycotest
Glycotest is a US based diagnostics company, developing biomarkers for clinical laboratory
services used in the diagnosis of liver cancers and fibrosis-cirrhosis, which the Directors
believe represents a $1 billion market opportunity. Its blood-based biomarkers take advantage
of sugar-related disease signals and the company has issued patents to over 50 serum proteins
with sugar structures that are altered in liver disease. The biomarkers are being developed into
tests and test panels intended for the surveillance of patients with serious liver disease.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEDEEIFWSEDM
(END) Dow Jones Newswires
June 26, 2017 02:00 ET (06:00 GMT)
1 Year Netscientific Chart |
1 Month Netscientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
